/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | AKTXAkari Therapeutics P |
|---|---|
| Last close | $7.66close 2026-11-09 |
| Change % | +3.93%close 2026-11-09 |
| Market cap | $1.19Tclose 2026-11-09 |
| P/E | loss, no P/E |
| Revenue | $367877⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerExcludingAssessedTax As ofFY ending 2023-12-31 Filing8-K · 0000950170-24-104428 · filed 2024-09-06 Open the filing on EDGAR → |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | -39.5%FY to 2023-12-31, older period |
| Net income | $-17300000⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2025-12-31 FilingDEF 14A · 0001493152-26-027279 · filed 2026-06-04 Open the filing on EDGAR →Open the XBRL payload →CiteAkari Therapeutics Plc (AKTX), us-gaap:NetIncomeLoss: -17,300,000 USD, fiscal year ended 2025-12-31. Form DEF 14A, accession 0001493152-26-027279, filed 2026-06-04. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001541157/us-gaap/NetIncomeLoss.json |
| Net margin | periods differ |
| EPS (diluted) | $0.00⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2025-12-31 Filing10-K · 0001493152-26-013664 · filed 2026-03-30 Open the filing on EDGAR →Open the XBRL payload →CiteAkari Therapeutics Plc (AKTX), us-gaap:EarningsPerShareDiluted: 0.00 USD per share, fiscal year ended 2025-12-31. Form 10-K, accession 0001493152-26-013664, filed 2026-03-30. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001541157/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | 2FY to 2023-12-31, older period |
| Altman Z-ScoreUNVALIDATED | 156080.44FY to 2023-12-31, older period |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | rep. 08-13 |